Synergy CHC Corp. announced that it has expanded its international licensing deal with Gravity Pharma, adding Turkey alongside the United Arab Emirates UAE for exclusive distribution of FOCUSfactor. This move brings total upfront licensing revenue to $2 million, with additional performance-based royalties tied to product sales across both high-growth markets.
The UAE-Turkey licensing model allows Synergy to scale the FOCUSfactor brand--including brain health supplements, cognitive beverages, and energy shots--without diluting ownership or diverting U.S.-based operational focus. Synergy retains 100% ownership and global IP, with performance-based royalties driving long-term upside. Key Highlights for Investors: $2M in licensing secured; Additional revenue potential through royalties; Scalable, asset-light growth strategy; Brain health market expected to top $20B by 2030.
With global demand for cognitive health solutions surging and strategic distribution partnerships now active, Synergy is well-positioned to capitalize on both brand strength and macro health trends. These developments follow key leadership hires from Coca-Cola's global beverage team, reinforcing the Company's commitment to accelerated growth and operational precision.
